Profit Margin (Quarterly) Chart

View Profit Margin (Quarterly) for BIIB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Profit Margin (Quarterly) Chart
Start Trial

Historical Profit Margin (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 3.72%
March 31, 2026 13.29%
December 31, 2025 -2.24%
September 30, 2025 19.00%
June 30, 2025 24.78%
March 31, 2025 10.30%
December 31, 2024 11.41%
September 30, 2024 16.35%
June 30, 2024 24.80%
March 31, 2024 17.88%
December 31, 2023 10.82%
September 30, 2023 -2.80%
June 30, 2023 25.24%
March 31, 2023 16.63%
December 31, 2022 22.04%
September 30, 2022 49.49%
June 30, 2022 44.01%
March 31, 2022 9.20%
December 31, 2021 -0.79%
September 30, 2021 12.01%
June 30, 2021 39.03%
March 31, 2021 16.22%
December 31, 2020 38.42%
September 30, 2020 22.57%
June 30, 2020 47.22%
Date Value
March 31, 2020 44.12%
December 31, 2019 44.21%
September 30, 2019 48.75%
June 30, 2019 46.60%
March 31, 2019 45.73%
December 31, 2018 30.01%
September 30, 2018 46.71%
June 30, 2018 30.50%
March 31, 2018 41.60%
December 31, 2017 -5.54%
September 30, 2017 44.24%
June 30, 2017 31.63%
March 31, 2017 30.14%
December 31, 2016 22.61%
September 30, 2016 38.73%
June 30, 2016 40.88%
March 31, 2016 40.29%
December 31, 2015 29.75%
September 30, 2015 42.23%
June 30, 2015 41.51%
March 31, 2015 37.11%
December 31, 2014 33.60%
September 30, 2014 38.25%
June 30, 2014 33.76%
March 31, 2014 25.78%

Profit Margin Definition

Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.

Read full definition.

Profit Margin (Quarterly) Range, Past 5 Years

View Profit Margin (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Profit Margin (Quarterly) Benchmarks

View Profit Margin (Quarterly) Benchmarks
Start Trial
Ionis Pharmaceuticals, Inc. -42.79%
AbbVie, Inc. 21.21%
Gilead Sciences, Inc. -134.2%
Vertex Pharmaceuticals, Inc. 32.89%
Amgen, Inc. 23.59%